Background-Among patients treated with clopidogrel, carriers of the cytochrome P450 (CYP) 2C19 loss-of-function allele have shown increased platelet reactivity and higher rates of ischemic events. Although adjunctive cilostazol to dual antiplatelet therapy (or "triple antiplatelet therapy") intensifies platelet inhibition, it remains unknown whether triple antiplatelet therapy after percutaneous coronary intervention can achieve adequate platelet inhibition in patients with the CYP2C19 mutant allele. Methods and Results-CYP2C19 genotyping for *1, *2, and *3 was performed in 134 high-risk patients undergoing elective percutaneous coronary intervention. After measurement of preprocedural platelet reactivity, patients were randomly assigned to receive either adjunctive cilostazol 100 mg twice daily (triple group; nϭ69) or high maintenance-dose (MD) clopidogrel of 150 mg daily (high-MD group; nϭ65). Using light transmittance aggregometry and the VerifyNow P2Y 12 assay, platelet reactivity was assessed before the index procedure and at 30-day follow-up. The primary end point was absolute change in maximal platelet aggregation (⌬Agg max ) according to CYP2C19 genotyping. High posttreatment platelet reactivity was defined as 5 mol/L ADP-induced maximal platelet aggregation Ͼ50%. In noncarriers of the CYP2C19*2/*3 mutant allele, ⌬Agg max values after 5 and 20 mol/L ADP stimuli did not differ significantly between the triple (nϭ22) versus the high-MD group (nϭ22) (23.6Ϯ21.6% versus 16.6Ϯ15.4%, Pϭ0.224 and 26.4Ϯ22.2% versus 18.6Ϯ14.9%, Pϭ0.174, respectively). Absolute changes in late platelet aggregation and P2Y 12 reaction unit were not different between the groups. The rate of high posttreatment platelet reactivity at 30-day follow-up also was comparable between the triple versus the high-MD group (4.5% versus 13.6%, Pϭ0.607). In carriers of at least 1 CYP2C19*2/*3 mutant allele, the triple group (nϭ47) showed greater values of ⌬Agg max after addition of 5 mol/L (25.8Ϯ16.8% versus 11.1Ϯ19.8%, PϽ0.001) and 20 mol/L ADP (26.3Ϯ16.0% versus 11.5Ϯ16.3%, PϽ0.001) compared with the high-MD group (nϭ43). Likewise, absolute changes in late platelet aggregation and P2Y 12 reaction unit were consistently greater in the triple versus the high-MD group. Fewer patients in the triple group met the criteria of high posttreatment platelet reactivity at 30-day follow-up compared with the high-MD group (6.4% versus 37.2%, PϽ0.001). Conclusions-Among high-risk patients undergoing elective percutaneous coronary intervention, adjunctive cilostazol can achieve consistently intensified platelet inhibition and reduce the risk of high posttreatment platelet reactivity irrespective of CYP2C19 genotyping. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01012193. (Circ Cardiovasc Interv. 2010;3:450-459.) 
ity in antiplatelet response to clopidogrel, 4 -6 and increased platelet reactivity despite clopidogrel is associated with a higher risk of ischemic events including stent thrombosis. 6 -9 Furthermore, patients with suboptimal response to clopidogrel also have a higher rate of aspirin resistance, which may increase the risk of thrombotic complications. 10, 11 Although various factors can affect response to clopidogrel, polymorphisms of alleles related with absorption and metabolism can decrease the thiol metabolite level of clopidogrel, which may lead to low inhibition of ADP-induced platelet reactivity. 12, 13 Of those, the hepatic cytochrome P450 (CYP) mutant alleles, especially the dominant CYP2C19 isoenzyme, have shown an association with increased platelet reactivity and consequent risk of major adverse cardiovascular events. 14 -17 Clinical Perspective on p 459
The Adjunctive Cilostazol versus High Maintenance-dose (MD) Clopidogrel (ACCEL) trials have demonstrated that adjunctive cilostazol can intensify platelet inhibition and reduce the rate of high posttreatment platelet reactivity (HPPR) in high-risk patients compared with high-MD clopidogrel of 150 mg daily. 18, 19 Cilostazol is a unique antiplatelet agent that acts by selective dual inhibition of phosphodiesterase type 3 (PDE3) and adenosine uptake in various cardiovascular systems. 20 Unlike other antiplatelet agents, cilostazol not only inhibits platelet aggregation 20 but also has favorable pleiotropic effects on neointimal hyperplasia after PCI 21 and the diverse processes of atherosclerosis. [22] [23] [24] Furthermore, cilostazol is mainly converted into the active metabolites by the CYP3A system, 25 which might imply less impact of the CYP2C19 mutant allele for additive platelet inhibition with cilostazol.
Although there are numerous studies providing evidences for the beneficial role of cilostazol, it remains unknown whether adjunctive cilostazol to dual antiplatelet therapy (or "triple antiplatelet therapy") in PCI-treated patients can achieve adequate platelet inhibition irrespective of the CYP2C19 loss-of-function allele carriage. If adjunctive cilostazol shows potency to surmount the risk of clopidogrel resistance in carriers of the CYP2C19 variant, triple antiplatelet therapy could be an optimal antithrombotic regimen. We thus performed the present study to assess the degree of intensified platelet inhibition by adjunctive cilostazol according to CYP2C19 genotyping in high-risk patients treated with PCI.
Methods

Patient Population
Between January 2008 and June 2009, patients were recruited at the Department of Cardiology of the Gyeongsang National University Hospital (Jinju, Korea). In the setting of elective PCI, 150 patients were prospectively enrolled in the ACCEL trials, 18 which were performed to compare the degree of platelet inhibition by adjunctive cilostazol with dual antiplatelet therapy versus high-MD clopidogrel in high-risk patients such as HPPR, diabetes, and drug-eluting stent implantation for complex lesions. 18 For the prespecified analysis, 134 patients (89.3%) of the cohort with available deoxyribonucleic acid (DNA) genotyping were recruited, which constituted the study subjects. Compared with patients enrolled in this study, 16 patients who could not undergo DNA genotyping (10.7%) did not show any difference in terms of baseline characteristics (PϾ0.05).
Patients were eligible for enrollment if they were Ն18 years of age and identified to have the enrolled criteria (HPPR, diabetes, or drug-eluting stent for complex lesions). Exclusion criteria were (1) acute myocardial infarction or hemodynamic instability; (2) active bleeding and bleeding diatheses; (3) warfarin therapy; (4) use of periprocedural glycoprotein IIb/IIIa inhibitors; (5) contraindication to antiplatelet therapy; (6) left ventricular ejection fraction Ͻ30%; (7) leukocyte count Ͻ3000/mm 3 and/or platelet count Ͻ100 000/ mm 3 ; (8) aspartate aminotransferase or alanine aminotransferase level Ն3 times the upper normal limit; (9) serum creatinine level Ն2.5 mg/dL; (10) stroke within 3 months; (11) noncardiac disease with a life expectancy Ͻ1 year; and (12) inability to follow the protocol. The institutional review board approved the study protocol, and the patients provided written informed consent for participation. The present study protocol complies with the Declaration of Helsinki and was approved by the Institutional Ethics Committee of the Gyeongsang National University Hospital. All of the patients provided written informed consent for the intervention, platelet function assays, and DNA genotyping.
Study Design
This ACCEL-POLYMORPHISM (Adjunctive Cilostazol versus High-MD Clopidogrel According to the CYP2C19 Polymorphism) study is an analysis of the subjects drawn from the prospective, randomized, parallel-group platelet function trials. The flow diagram of the study is illustrated in Figure 1 . All patients received a 300-mg loading dose of clopidogrel at least 12 hours before PCI (nϭ98) or were receiving chronic clopidogrel therapy (75 mg daily for Ն7 days, nϭ36). All patients received a 300-mg loading dose of aspirin, followed by 200 mg daily for 1 month. Whole blood for preprocedural platelet measures was obtained immediately after insertion of the arterial sheath in the catheterization room. Diagnostic and interventional procedures were performed according to standard techniques. In patients with multiple lesions, the first treated lesion was considered as the target lesion.
If subjects met the inclusion criteria, they were randomly assigned to adjunctive cilostazol (triple group) or high-MD clopidogrel (high-MD group) using a computer-generated randomization table. The triple group (nϭ69) received adjunctive cilostazol 100 mg twice daily to clopidogrel 75 mg daily for 30 days. The high-MD group (nϭ65) received clopidogrel 150 mg daily for 30 days. At the 30-day follow-up visit, patient compliance to antiplatelet therapy was assessed by interview and pill counting. Blood samples also were obtained 2 to 4 hours after the last drug ingestion. Peripheral venous blood samples were drawn through a venous catheter inserted into a forearm vein.
CYP2C19 Genotyping
Base numbering and allele definitions followed the nomenclature of the Human CYP Allele Nomenclature Committee. 26 Genomic DNA was extracted from leukocytes of whole-blood specimens with an extraction kit (QIAamp DNA Blood Mini Kit, Qiagen, Hilden, Germany). Because the allelic frequencies of the CYP2C19*4 to *6 are extremely rare in East Asians, 27, 28 genotyping for CYP2C19*2 (rs4244285, c.681GϾA) and CYP2C19*3 (rs4986893, c.636GϾA) were conducted using single base primer extension assay using SNaPshot assay kit (Applied Biosystems, Foster City, Calif). 29 Briefly, the genomic DNA region containing 1 of the 2 single nucleotide polymorphism (SNP) was amplified with polymerase chain reaction (PCR) separately. PCR was carried out by using the same primers as previously described. The PCR product was processed as per the ABI SNaPshot protocol, using primers designed for fluorescent dideoxy nucleotide termination. SNP analysis was carried out on the ABI 3100 genetic analyzer.
Platelet Function Assays
Blood samples were collected using the double-syringe technique, in which the first 2 to 4 mL of blood was discarded to avoid spontaneous platelet activation. Platelet reactivity was simultaneously measured by light transmittance aggregometry and the VerifyNow P2Y 12 assay (Accumetrics Inc, San Diego, Calif). Correlation between 2 methods at our laboratory has been previously reported. 30 Light transmittance aggregometry was performed according to standard protocol, as described in detail. 18, 19 Blood samplings were drawn into Vacutainer tubes containing 0.5 mL of 3.2% sodium citrate (Becton-Dickinson, San Jose, Calif), and the samples were processed within 60 minutes. Platelet-rich plasma (PRP) was obtained as a supernatant fluid after centrifuging the blood at 120g for 10 minutes. The remaining blood was further centrifuged at 1200g for 10 minutes to prepare platelet-poor plasma (PPP). PRP was adjusted to platelet counts of 250 000/mm 3 by adding PPP as needed. Platelet aggregation was assessed at 37°C using an AggRAM aggregometer (Helena Laboratories Corp, Beaumont, Tex). Tests were performed after the addition of 5 and 20 mol/L ADP, and the curves were recorded for 10 minutes. Platelet reactivity was measured at the peak (maximal platelet aggregation; Agg max ) and at 5 minutes (late platelet aggregation; Agg late ) by laboratory personnel blinded to the study protocol. Absolute changes in platelet aggregation (⌬Agg max and ⌬Agg late ) were defined as changes of values between preprocedural and 30-day follow-up time points: ⌬Aggϭ(preprocedural platelet aggregationϪplatelet aggregation at 30-day follow-up).
The VerifyNow P2Y 12 assay is a whole-blood, point-of-care system. 8 Blood was drawn into a Greiner Bio-One 3.2% citrate Vacuette tube (Greiner Bio-One, Kremsmünster, Austria). The assay consists of 2 whole-blood channels containing fibrinogen-coated polystyrene beads. One contains 20 mol/L ADP and 22 nmol/L PGE 1 to reduce the nonspecific contribution of other pathways. The other channel contains iso-thrombin receptor activating protein (iso-TRAP), and a baseline value (BASE) is obtained. The results are reported in P2Y 12 
End Points and Definitions
The primary end point was ⌬Agg max according to CYP2C19 genotyping. Secondary end points were (1) ⌬Agg late ; (2) ⌬PRU; and (3) the rate of HPPR at 30-day follow-up according to CYP2C19 genotyping. In addition, we assessed the composite of death, acute myocardial infarction, urgent target vessel revascularization, or stent thrombosis during 30-day follow-up. Bleeding was defined accord-ing to the criteria used in the Thrombolysis in Myocardial Infarction trials. HPPR was defined as 5 mol/L ADP-induced Agg max Ͼ50% of light transmission. 18, 19, 31 Because a 5 mol/L ADP-induced Agg max Ͼ50% was similar to a PRU value Ն235 based on previously reported data, 30 this threshold of HPPR might be an acceptable level of suboptimal response. Patients without the CYP2C19*2/*3 mutant allele were categorized as wild-type homozygotes (wt/wt). Mutant-type variants consisted of carriers with 1 (wt/*2 or wt/*3) and 2 CYP2C19 mutant allele (*2/*2, *3/*3 or *2/*3). 29
Sample Size Calculation and Statistical Analysis
The sample size calculation was based on the observed 5 mol/L ADP-induced ⌬Agg max (31.8) by adjunctive cilostazol and on the observed 5-mol/L ADP-induced ⌬Agg max (17.2) by high-MD clopidogrel. 18 Based on previous studies, 29 prevalence of wild-type homozygotes was considered as approximately 40% in the East Asian population. To detect such a 45.9% relative difference in 5 mol/L ADP-induced ⌬Agg max with a power of 95% and a 2-sided ␣ value of 0.05, we calculated that we need to include at least 16 noncarriers of the CYP2C19*2/*3 mutant allele. Thus, the needed study population was estimated as a total of 80 patients including 16 noncarriers and 24 carriers of the CYP2C19 variant allele for each treatment group. Continuous variables are expressed as meanϮSD, and their differences were tested using the Student unpaired t, Wilcoxon signed rank, or Mann-Whitney U tests. Categorical variables are expressed as frequencies and percentages, and 2 statistics or Fisher exact test was used for their comparisons (if an expected frequency was Ͻ5). We calculated Hardy-Weinberg equilibrium proportions using the Pearson goodness-of-fit 2 statistics to test a possible deviation of the CYP2C19 genotype distribution. To adjust potential confounding variables in comparison of the end points, logistic regression analysis was performed including age, sex, body mass index, diabetes mellitus, hypertension, hypercholesterolemia, current smoking, chronic kidney disease, previous myocardial infarction, calcium channel blocker, left ventricular ejection fraction Ն45%, multivessel disease, American College Cardiology/American Heart Association (ACC/AHA) lesion type B2/C, and total stent length. Statistical analyses were performed using SPSS version 13 (SPSS Inc, Chicago, Ill) and conducted at the 0.05 significance level.
Results
Patient Characteristics and Follow-Up
Because we recruited the study subjects from the cohort of the ACCEL trials, platelet function measurements at 30-day follow-up was available for all enrolled subjects ( Figure 1 ). Although there were 4 cases of transient headache and 2 cases of palpitation in the triple group in the early phase of treatment, all regimens were generally well tolerated and no patients discontinued the study regimen during 30 days. Genetic distributions of the CYP2C19 polymorphisms were similar to the published East Asian frequencies, 26 and did not significantly deviate from Hardy-Weinberg equilibrium (CYP2C19*2: Pϭ0.33 and CYP2C19*3: Pϭ0.80, respectively). As expected, [27] [28] [29] carriage of the CYP2C19 mutant allele (*2 or *3) was relatively high, 67.2% of total (nϭ90) (see the Appendix in the online-only Data Supplemental Table 1 ): 63 carriers with 1 mutant allele (47.0%: nϭ31 in the high-MD group and nϭ32 in the triple group) and 27 carriers with 2 mutant alleles (20.2%: nϭ12 in the high-MD group and nϭ15 in the triple group), and 44 wild-type homozygotes (wt/wt) (32.8%: nϭ22 in the high-MD group and nϭ22 in the triple group). There were no differences in preprocedural platelet measures between carriers of the CYP2C19*2 versus *3 variant allele (see the Appendix in the online-only Data Supplemental Tables 2 and 3 ). The triple group consisted of 22 wild-type homozygotes and 47 mutant-type variants (Figure 1) . The high-MD group consisted of 22 wild-type homozygotes and 43 mutant-type variants.
Baseline characteristics were well matched between the treatment groups according to CYP2C19 genotyping, except for a higher rate of ACC/AHA lesion type B2/C in the triple versus high-MD group of mutant-type variants ( Table 1) . Preprocedural values of platelet measures were similar between the treatment groups according to metabolizer and genotype status (Tables 2 and 3 ) (see the Appendix in the online-only Data Supplemental Tables 2 and 3 ). There were no differences in preprocedural platelet reactivity after 300-mg loading and chronic therapy of clopidogrel (see the Appendix in the online-only Data Supplemental Table 4 ). In addition, adjusting statistically did not change any of the end points, based on platelet function assays. During the follow-up period, no major ischemic and bleeding events were observed in any group.
Primary End Points
In wild-type homozygotes of the CYP2C19 allele, both treatment groups showed remarkable reductions in Agg max values at 30-day follow-up compared with preprocedural values (all values, PϽ0.001). After any of the tested concentrations of ADP stimuli, ⌬Agg max did not differ significantly between the triple versus high-MD group (Figure 2A ). ⌬Agg max with 5 mol/L ADP stimuli was 23.6Ϯ21.6% in the triple group and 16.6Ϯ15.4% in the high-MD group (Pϭ0.224), whereas it was 26.4Ϯ22.2% and 18.6Ϯ14.9% with 20 mol/L ADP stimuli, respectively (Pϭ0.174).
In mutant-type variants of the CYP2C19 allele, both treatment regimens also reduced significantly Agg max values at 30-day follow-up compared with preprocedural values (all values, PϽ0.001). Triple antiplatelet therapy showed greater values of ⌬Agg max in the addition of 5 mol/L (25.8Ϯ16.8% versus 11.1Ϯ19.8%, PϽ0.001) and 20 mol/L ADP (26.3Ϯ16.0% versus 11.5Ϯ16.3%, PϽ0.001), compared with high-MD clopidogrel ( Figure 2B ).
Secondary End Points
Compared with preprocedural values of Agg late , Agg late values at 30-day follow-up were also significantly reduced by both regimens irrespective of CYP2C19 genotyping (all values, PϽ0.001). For wild-type homozygotes of the CYP2C19 allele, ⌬Agg late in the triple group was not significantly higher than that in the high-MD group ( Figure 3A) . Values of ⌬Agg late after 5 mol/L ADP stimuli were Data are presented as meanϮSD. Figure 3B ): 29.1Ϯ18.9% versus 16.4Ϯ23.2% after the addition of 5 mol/L ADP (Pϭ0.005) and 34.5Ϯ19.0% versus 17.8Ϯ20.9% after the addition of 20 mol/L ADP (PϽ0.001). At 30-day follow-up, both groups presented significantly lower PRU and higher percent inhibition as compared with preprocedural values irrespective of CYP2C19 genotyping (all values, PϽ0.001). In wild-type homozygotes of the CYP2C19 allele, ⌬PRU did not significantly differ according to the regimens (124.4Ϯ84.6 in the triple group versus 122.7Ϯ72.1 in the high-MD group, Pϭ0.945) ( Figure 4A ). However, triple antiplatelet therapy considerably enhanced ⌬PRU more than high-MD clopidogrel in mutant-type variants of the CYP2C19 allele (104.8Ϯ74.6 versus 64.2Ϯ75.7, Pϭ0.012) ( Figure 4B ).
Both regimens could reduce significantly the rate of HPPR at 30-day follow-up compared with preprocedural values irrespective of CYP2C19 genotyping (all values, PϽ0.001). Among wild-type homozygotes of the CYP2C19 allele, no differences between the triple versus high-MD group were seen at preprocedure (63.6% versus 45.5%, Pϭ0.226) and 30-day follow-up (4.5% versus 13.6%, Pϭ0.607) ( Figure  5A ). Among mutant-type variants of the CYP2C19 allele, there was no difference for preprocedural rate of HPPR between the triple versus high-MD group (68.1% versus 65.1%, Pϭ0.765) ( Figure 5B ). However, the triple group demonstrated the lower rate of HPPR at 30-day follow-up as compared with the high-MD group (6.4% versus 37.2%, PϽ0.001).
Effect of CYP2C19 Genotyping Within Treatment Groups
In the high-MD group, even though differences did not reach statistical significance, wild-type homozygotes showed a trend toward higher values of 5 and 20 mol/L ADPstimulated ⌬Agg max than mutant-type variants (16.6Ϯ15.4% versus 11.1Ϯ19.8%, Pϭ0.263 and 18.6Ϯ14.9% versus 11.5Ϯ16.3%, Pϭ0.092, respectively). ⌬Agg late values after 5 and 20 mol/L ADP stimuli also showed trends toward higher values in wild-type homozygotes compared with mutant-type variants (21.4Ϯ19.3% versus 16.4Ϯ23.2%, Pϭ0.292, and 25.3Ϯ19.6% versus 17.8Ϯ20.9%, Pϭ0.169, respectively). ⌬PRU in wild-type homozygotes was significantly greater than that of mutant-type variants (122.7Ϯ72.1 versus 64.2Ϯ75.7, Pϭ0.004). Wild-type homozygotes showed the lower rate of HPPR at 30-day follow-up compared with mutant-type variants (13.6% versus 37.2%, Pϭ0.048). In the triple group, wild-type homozygotes did not differ with mutant-type variants in terms of 5 and 20 mol/L ADP-stimulated ⌬Agg max (23.6Ϯ21.6% versus 25.8Ϯ16.8%, Pϭ0.641, and 26.4Ϯ22.2% versus 26.3Ϯ16.0%, Pϭ0.980, respectively). ⌬Agg late values also were not different between wild-type homozygotes and mutant-type variants: 26.1Ϯ21.3% versus 29.1Ϯ18.9% after 5 mol/L ADP stimuli (Pϭ0.556) and 33.0Ϯ24.0% versus 34.5Ϯ19.0% after 20 mol/L ADP stimuli (Pϭ0.788). In addition, wild-type homozygotes showed similar values of ⌬PRU (124.4Ϯ84.6 versus 104.8Ϯ74.6, Pϭ0.334) and the 30-day rate of HPPR (4.5% versus 6.4%, Pϭ1.000), compared with mutant-type variants.
Discussion
To the best of our knowledge, this ACCEL-POLYMORPHISM study is the first to demonstrate the impact of adjunctive cilostazol on intensified platelet inhibition according to CYP2C19 genotyping in high-risk patients undergoing elective PCI. Major findings of the present study are (1) adjunctive cilostazol to dual antiplatelet therapy can achieve acceptable platelet inhibition and reduce the risk of HPPR in both noncarriers and carriers of the CYP2C19 mutant allele; (2) additive platelet inhibition by adjunctive cilostazol may not be influenced by CYP2C19 genotyping; and (3) antiplatelet response to high-MD clopidogrel may be influenced by carriage of the CYP2C19 mutant allele.
Because all biological processes reflect the combined influence of multiple clinical, environmental, and genetic effects, antiplatelet response to a prodrug clopidogrel also can be influenced by various factors. 32 Because a small proportion of the ingested clopidogrel finally binds to P2Y 12 receptor, small changes in absorption, metabolism, and P2Y 12 receptor density can considerably affect residual platelet reactivity. 33 Furthermore, because HPPR increases the risk of ischemic events, 6 -9 there remains a critical need to achieve adequate platelet inhibition in high-risk patients. Although concomitant disease processes, drug-drug interaction, and clinical factors are associated with increased on-treatment platelet reactivity, 12, 13, 32 genetic polymorphisms, especially the CYP2C19 variant carriage, have been identified to be major predictors of HPPR and adverse clinical events in PCI-treated patients. 14 -17 Antiplatelet regimens to overcome the loss-of-function effect of the CYP2C19 mutant allele have been under investigation. 34 The present study suggests that enhanced platelet inhibition by adjunctive cilostazol may not be influenced by CYP2C19 polymorphism. The pathway related with active conversion of cilostazol can explain this observation. The major active metabolites of cilostazol are OPC-13015 (dehydrocilostazol) and OPC-13213 (monohydroxy-cilostazol). 25 OPC-13015 is mainly produced by the CYP3A4 system, and it is 3 times more potent than cilostazol. On other hand, OPC-13213 is produced by the CYP3A4/5 and CYP2C19 pathways, and it is 3 times less potent than cilostazol. Therefore, the active metabolite of cilostazol may be consistently produced with little effect from the CYP2C19 variant, which may be related with consistently achieved platelet inhibition irrespective of CYP2C19 genotyping.
Recent studies have suggested a possibility that enhanced responsiveness to clopidogrel is associated with a higher risk of major bleeding. 35, 36 Thus, it is imperative to maximize efficacy and maintain safety by defining unidentified therapeutic window for P2Y 12 inhibition. 32 Although novel and more potent P2Y 12 inhibitors including prasugrel and ticargrelor can overcome the limitations of clopidogrel, the benefits of these agents were associated with the increased rates of major bleeding compared with clopidogrel. 37, 38 Interestingly, there are no reports of the increased risk of major or fatal bleeding by adjunctive cilostazol. 39 -41 This finding might be explained by an endothelium-targeted antithrombotic therapy, which reduces the number of partially activated platelets by interacting with activated endothelial cells. 20 In addition, a previous report documented that adjunctive cilostazol to other antiplatelet regimen did not prolong bleeding time. 42 Cilostazol also has the relatively short recovery time of platelet function. 20 Although it is hard to establish because of the lack of large clinical data, adjunctive cilostazol might be an option if there are worrisome risks of bleeding with novel and more potent P2Y 12 inhibitors.
Because atherothrombosis is initiated and propagated by cross-talk of multiple causes, only intensified platelet inhibition cannot guarantee the escape from atherothrombosis. As aforementioned, cilostazol is known as a unique selective dual inhibitor of PDE3 and adenosine uptake, which causes elevation of cyclic AMP (cAMP) in various cardiovascular systems. 20 Therefore, cilostazol not only inhibits platelet aggregation 20 but also has favorable pleiotropic effects on the diverse processes in preclinical studies. [22] [23] [24] Adjunctive cilostazol can reduce aspirin and clopidogrel resistance in patients with vascular disease 18, 19, 43 Cilostazol not only can inhibit oxidative stress and inflammatory burden 23, 44 but also can protect from endothelial senescence and dysfunction. 22, 24 Enhancement of endothelial nitric oxide synthase by cilostazol underlies its vasodilating property, 22 which is used for intermittent claudication and cerebral infarction. 45 In addition, cilostazol can inhibit smooth muscle cell proliferation after vascular stenting, 21, 46 and protect myocardium against ischemia-reperfusion injury. 47 Finally, cilostazol also can elevate circulating adenosine levels, 20 which is suggested as a mechanism for superiority of ticagrelor to prasugrel in terms of cardiovascular mortality. 48 The clinical impact of triple antiplatelet therapy has been proven mostly for an East Asian population. Because the CYP2C19 variant is more prevalent in East Asians than whites (Ϸ60% versus Ϸ30%), 14 -17,29 the benefit of this regimen may be somewhat related with ethnic singularity. Because the effect of clopidogrel dose-up may be more influenced by the CYP2C19 variant carriage, adjunctive cilostazol can be a more useful intensified antiplatelet therapy in East Asian patients compared with high-MD clopidogrel. In addition, cilostazol also might provide valuable effects on endothelium protection and antiatherogenic milieu. Therefore, triple antiplatelet therapy conceptually can be an optimal antiplatelet regimen for PCI-treated patients in high-risk clinical or lesion subsets. However, this concept would be acceptable in clinical practice if global scaled, large, prospective studies can verify this conceptual efficacy and safety.
Study Limitations
First, the follow-up period was short and the number of patients studied was small. In addition, variations of anti- platelet response during initial clopidogrel maintenance therapy might have influenced absolute changes of platelet measures. Second, preprocedural use of clopidogrel (300-mg loading versus chronic therapy) was relatively heterogeneous. However, preprocedural platelet reactivity was similar between the 2 treatments. Third, the present study including East Asians only showed laboratory data and could not suggest any result of clinical outcomes caused by enrollment of patients undergoing uneventful PCI and the number of cohorts. The present study also may not suggest the optimal duration of intensified antiplatelet therapy in high-risk patients. Fourth, we performed CYP2C19 genotyping only, and we could not absolutely exclude the impact of other genetic polymorphisms. Finally, the present study is a post hoc analysis of subjects drawn from prospective trials.
Conclusion
Among high-risk patients undergoing elective PCI, adjunctive cilostazol can achieve consistently intensified platelet inhibition and reduce the risk of HPPR irrespective of CYP2C19 genotyping.
